



Gadolinium

(MRI Contrast Agent)

Gadolinium Based Contrast Agent (GBCA) is an intravenous drug used during Magnetic Resonance Imaging (MRI) or Magnetic Resonance Angiography (MRA) to enhance the quality of the image. The GBCAs allow a healthcare professional to accurately diagnose conditions such as cancer, infections, or bleeding. The GBCA is supposed to be cleared through the kidneys, however, there are two kinds of GBCAs, one of which is retained in the body longer than the manufacturers had originally anticipated.

What You Should Know

The type of GBCA matters because **linear** GBCAs are less stable and release gadolinium ions whereas **macrocylic** GBCAs tend to stay intact. We are retaining clients where a linear GBCA has been injected.

The FDA has acknowledged that a portion of the GBCA is retained in the body. The retention of gadolinium in the body can result in Gadolinium Deposition Disease (GDD) where individuals with normal or near normal renal function develop persistent symptoms that arise within **two months** after the administration of GBCAs.



The **symptoms** of GDD can include:

- Persistent headache
- Bone and joint pain
- “Brain Fog”
- Skin that appears spongy or rubbery
- Painful and thickened tendons and ligaments
- Tightness in hands and feet
- Burning, cutting, or pins-and-needles sensation



Can I make a claim against the manufacturers?

Showard Law Firm is currently accepting claims against Bayer (Magnevist & Eoist), GE (Omniscan), Bracco (Multihance), and Guerbet (Optimark)

4703 E. Camp Lowell Dr., Ste. 253 Tucson, AZ 85712

(520)622-3344

www.showardlaw.com

